Contrasting QHSLab (USAQ) & Its Peers

Volatility and Risk

QHSLab has a beta of -0.66, suggesting that its share price is 166% less volatile than the S&P 500. Comparatively, QHSLab’s rivals have a beta of 0.45, suggesting that their average share price is 55% less volatile than the S&P 500.

Earnings and Valuation

This table compares QHSLab and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
QHSLab	$1.41 million	-$470,000.00	-15.00
QHSLab Competitors	$1.05 billion	$10.63 million	-6.68

QHSLab’s rivals have higher revenue and earnings than QHSLab. QHSLab is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares QHSLab and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QHSLab	-3.24%	N/A	-3.43%
QHSLab Competitors	-574.62%	-156.70%	-27.31%

Institutional and Insider Ownership

47.9% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 74.2% of QHSLab shares are held by insiders. Comparatively, 15.5% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

QHSLab rivals beat QHSLab on 5 of the 9 factors compared.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.